BioNexus Gene Lab Corp. filings document material-event disclosures for its precision diagnostics strategy, subsidiary governance, capital structure, and periodic reporting obligations. Recent 8-K filings cover VitaGuard™ MRD commercialization activity, the Fidelion Diagnostics relationship, Chemrex governance restructuring, strategic partnership disclosures, and exhibits tied to company press releases and material agreements.
The company’s filing record also includes Form 12b-25 notifications for delayed periodic reports, with explanations tied to financial-reporting transitions and enhanced transaction review. Capital-structure disclosures include registration and equity financing arrangements, while governance disclosures address parent-level oversight, subsidiary board accountability, reporting protocols, and reporting-control processes.
BioNexus Gene Lab Corp (BGLC) 10-Q excerpts show corporate and balance-sheet details without full financial statements. The company reports 300,000,000 shares authorized with 1,796,597 shares outstanding in one period and 1,796,766 shares outstanding at December 31, 2024 (post-reverse split basis). The company disclosed the 2017 acquisition of Bionexus Gene Lab Sdn. Bhd., later renamed MRNA Scientific Sdn. Bhd. It records trade receivables at invoiced amounts less an allowance for expected credit losses, writes off uncollectible accounts, and notes typical receivable terms range from 30 to 90 days. One customer was charged interest at 6% per annum through June 2023 and the rate increased to 8.4% from July 2023. The filing notes 1,044,351 shares issued due to a round-up and corporate governance actions at subsidiary Chemrex Corporation Sdn. Bhd., including additional directors, policy updates, and enhanced reporting to the company CFO and Audit Committee.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) filed an 8-K to disclose a Regulation FD communication. On 30 July 2025 the company signed a non-binding term sheet with Singapore-based Fidelion Diagnostics Pte Ltd. The parties are negotiating a cross-equity strategic alliance and have granted BGLC exclusive commercialization rights in Southeast Asia to Fidelion’s VitaGuard™ minimal-residual-disease (MRD) testing platform, a precision-oncology technology aimed at detecting trace cancer cells post-treatment.
The agreement is still preliminary; no financial terms, timelines or definitive contracts were announced. The company framed the deal as a potential “DeepSeek Moment” for oncology diagnostics in the region. No guidance, revenue impact or financing details accompanied the disclosure, and the item is being furnished, not filed, so it carries no immediate accounting effect.